Bicycle Therapeutics Debt 2024

Bicycle Therapeutics Aktienanalyse

What does Bicycle Therapeutics do?

Bicycle Therapeutics PLC is a British biotechnology company specializing in the development of innovative drugs for the treatment of cancer and other diseases. The company was founded in 2009 by Sir Greg Winter, John McCafferty, and Sir Tom Blundell. They discovered a new class of molecules called Bicycles, which are small enough to penetrate the human body but large enough to selectively bind to cells and tissues and influence their biological functions. Bicycles are based on a technology called phage display, which allows for the targeted identification and isolation of molecules with specific properties. The business model of Bicycle Therapeutics revolves around using Bicycles as drug candidates for the development of new medications. The company collaborates with leading pharmaceutical and biotechnology companies to jointly develop new therapies, focusing primarily on cancer treatment due to the high demand for targeted therapies in this field. Bicycle Therapeutics has various divisions dedicated to the development of drugs for specific types of cancer. Immunoncology is one such division, which focuses on mobilizing the body's immune system to fight cancer. Another division, Targeted Payloads, concentrates on developing medications that specifically attack and destroy cancer cells. The company offers a range of products developed based on Bicycles, including therapeutic antibodies that selectively target and destroy cancer cells, as well as diagnostics for the early detection and diagnosis of cancer. One example of Bicycle Therapeutics' product is BT1718, a therapeutic antibody that specifically targets the membrane protein 5 (MP5). MP5 is expressed on the surface of various cancer cells and is therefore a promising target for cancer therapy. BT1718 has shown promising results in clinical studies involving patients with various types of cancer. Another example is BT5528, a targeted payload that targets the EphA2 receptor. EphA2 is expressed on the surface of different cancer cells and plays a crucial role in tumor progression. BT5528 is a molecule that specifically binds to EphA2 and releases a payload that attacks and destroys cancer cells. The product is currently in clinical development. Overall, Bicycle Therapeutics is a promising biotechnology company specializing in the development of innovative drugs for the treatment of cancer and other diseases. The company has a unique technology platform and collaborates with leading pharmaceutical and biotechnology companies to develop new therapies. With products like BT1718 and BT5528, Bicycle Therapeutics has already achieved promising results and remains an important player in the field of cancer therapy. Bicycle Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Bicycle Therapeutics's Debt Structure

Bicycle Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Bicycle Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Bicycle Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Bicycle Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Bicycle Therapeutics stock

What is the debt of Bicycle Therapeutics this year?

Bicycle Therapeutics has a debt level of -495.72 USD this year.

What was the debt of Bicycle Therapeutics compared to the previous year?

The debt of Bicycle Therapeutics has increased by 60.48% compared to the previous year increased.

What are the consequences of high debt for investors in Bicycle Therapeutics?

High debt can pose a risk for investors of Bicycle Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Bicycle Therapeutics?

Low debt means that Bicycle Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Bicycle Therapeutics affect the company?

An increase in debt of Bicycle Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Bicycle Therapeutics affect the company?

A reduction in debt of Bicycle Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Bicycle Therapeutics?

Some factors that can influence the debt of Bicycle Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Bicycle Therapeutics so important for investors?

The debts of Bicycle Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Bicycle Therapeutics take to change the debt?

To change the debt, Bicycle Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Bicycle Therapeutics pay?

Over the past 12 months, Bicycle Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bicycle Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Bicycle Therapeutics?

The current dividend yield of Bicycle Therapeutics is .

When does Bicycle Therapeutics pay dividends?

Bicycle Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bicycle Therapeutics?

Bicycle Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Bicycle Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bicycle Therapeutics located?

Bicycle Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bicycle Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bicycle Therapeutics from 9/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.

When did Bicycle Therapeutics pay the last dividend?

The last dividend was paid out on 9/26/2024.

What was the dividend of Bicycle Therapeutics in the year 2023?

In the year 2023, Bicycle Therapeutics distributed 0 USD as dividends.

In which currency does Bicycle Therapeutics pay out the dividend?

The dividends of Bicycle Therapeutics are distributed in USD.